相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype
C. Lu et al.
ANNALS OF ONCOLOGY (2020)
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
D. J. Khalaf et al.
ANNALS OF ONCOLOGY (2020)
Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis
Noriyoshi Miura et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Germline HSD3B1 Genetics and Prostate Cancer Outcomes
Lewis Thomas et al.
UROLOGY (2020)
Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
Michael J. Morris et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Bram De Laere et al.
CLINICAL CANCER RESEARCH (2019)
Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
Masaki Shiota et al.
JAMA NETWORK OPEN (2019)
Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving AndrogenDeprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial
Paul Toren et al.
CLINICAL CANCER RESEARCH (2018)
Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer
Andrew W. Hahn et al.
CLINICAL GENITOURINARY CANCER (2018)
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer
Mohammad Alyamani et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer
Russell Z. Szmulewitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate in Patients with Castration-resistant Prostate Cancer
Kotaro Suzuki et al.
ANTICANCER RESEARCH (2018)
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Gunther Boysen et al.
CLINICAL CANCER RESEARCH (2018)
Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients
E. Carton et al.
EUROPEAN JOURNAL OF CANCER (2017)
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer
Terence W. Friedlander et al.
CLINICAL GENITOURINARY CANCER (2017)
Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer
Elahe A. Mostaghel et al.
CLINICAL CANCER RESEARCH (2017)
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V. Conteduca et al.
ANNALS OF ONCOLOGY (2017)
A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer
Rana R. McKay et al.
CLINICAL CANCER RESEARCH (2016)
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study
Jason W. D. Hearn et al.
LANCET ONCOLOGY (2016)
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
Zhenfei Li et al.
NATURE (2016)
The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism
M. Shiota et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2016)
The 5α-Androstanedione Pathway to Dihydrotestosterone in Castration-Resistant Prostate Cancer
Nima Sharifi
JOURNAL OF INVESTIGATIVE MEDICINE (2016)
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer
Daniel Tamae et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2015)
PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
Roberta Ferraldeschi et al.
EUROPEAN UROLOGY (2015)
Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT
Laurence Klotz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CYB5A polymorphism increases androgens and reduces risk of rheumatoid arthritis in women
Klaus Stark et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens
Won Kim et al.
CLINICAL CANCER RESEARCH (2014)
Testosterone serum levels and prostate cancer prognosis: the double face of Janus
Francesca Valcamonico et al.
FUTURE ONCOLOGY (2014)
Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study
Mary-Ellen Taplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens
Colin C. Pritchard et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Kai-Hsiung Chang et al.
CELL (2013)
Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial
Charles J. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
David J. Mulholland et al.
CANCER CELL (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
Elahe A. Mostaghel et al.
CLINICAL CANCER RESEARCH (2011)
Deletions of the Androgen-Metabolizing UGT2B Genes Have an Effect on Circulating Steroid Levels and Biochemical Recurrence after Radical Prostatectomy in Localized Prostate Cancer
Genevieve Nadeau et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
Charles J. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
Alison H. M. Reid et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Genetic polymorphisms of MC2R gene associated with responsiveness to adrenocorticotropic hormone therapy in infantile spasms
Liu Zhan-li et al.
CHINESE MEDICAL JOURNAL (2008)
Association of SULT2A1 allelic variants with plasma adrenal androgens and prostate cancer in African American men
Teresa W. Wilborn et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2006)
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
DP Petrylak et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
The androgen axis in recurrent prostate cancer
JL Mohler et al.
CLINICAL CANCER RESEARCH (2004)
SF1 polymorphisms in the mouse and steroidogenic potential
BP Schimmer et al.
ENDOCRINE RESEARCH (2002)
分享论文
